Profile | GDS2987 / GI_19923918-S |
Title | Comparison of Rho kinase inhibitor and atorvastatin effects on primary cell lines |
Organism | Homo sapiens |
Sample | Title | Value | Rank |
---|---|---|---|
GSM214810 | HMVEC_vehicle_rep1 | 14.4 | 45 |
GSM215244 | HMVEC_vehicle_rep2 | 28.5 | 56 |
GSM215253 | HMVEC_vehicle_rep3 | 34.6 | 66 |
GSM215254 | HMVEC_atorvastatin_rep1 | 71.4 | 72 |
GSM215282 | HMVEC_atorvastatin_rep3 | 26.1 | 51 |
GSM215344 | HMVEC_atorvastatin_rep2 | 49.7 | 68 |
GSM215283 | HMVEC_atorvastatin_mevalonate_rep1 | 29 | 49 |
GSM215284 | HMVEC_atorvastatin_mevalonate_rep2 | 34.1 | 55 |
GSM215293 | HMVEC_atorvastatin_mevalonate_rep3 | 42.9 | 56 |
GSM215294 | HMVEC_SLx2119_rep1 | 21.7 | 58 |
GSM215295 | HMVEC_SLx2119_rep2 | 38.8 | 59 |
GSM215296 | HMVEC_SLx2119_rep3 | 49 | 61 |
GSM215297 | PASMC_vehicle_rep1 | 63.3 | 65 |
GSM215298 | PASMC_vehicle_rep2 | 45.5 | 56 |
GSM215310 | PASMC_vehicle_rep3 | 10.5 | 17 |
GSM215311 | PASMC_atorvastatin_rep1 | 20.4 | 34 |
GSM215312 | PASMC_atorvastatin_rep2 | 16.2 | 26 |
GSM215313 | PASMC_atorvastatin_rep3 | 67.9 | 67 |
GSM215324 | PASMC_atorvastatin_mevalonate_rep1 | 31.1 | 47 |
GSM215325 | PASMC_atorvastatin_mevalonate_rep2 | ||
GSM215326 | PASMC_atorvastatin_mevalonate_rep3 | 31.8 | 48 |
GSM215327 | PASMC_SLx2119_rep1 | 3.9 | 7 |
GSM215328 | PASMC_SLx2119_rep2 | 29.5 | 47 |
GSM215329 | PASMC_SLx2119_rep3 | 21.1 | 38 |
GSM215330 | Fibroblasts_vehicle_rep1 | 18.7 | 40 |
GSM215331 | Fibroblasts_vehicle_rep2 | 9.5 | 27 |
GSM215332 | Fibroblasts_vehicle_rep3 | 3 | 10 |
GSM215333 | Fibroblasts_atorvastatin_rep1 | 15.4 | 38 |
GSM215334 | Fibroblasts_atorvastatin_rep2 | 33.9 | 62 |
GSM215335 | Fibroblasts_atorvastatin_rep3 | ||
GSM215336 | Fibroblasts_atorvastatin_mevalonate_rep1 | ||
GSM215337 | Fibroblasts_atorvastatin_mevalonate_rep2 | 7 | 23 |
GSM215338 | Fibroblasts_atorvastatin_mevalonate_rep3 | 14.8 | 39 |
GSM215339 | Fibroblasts_SLx2119_rep1 | 13.7 | 38 |
GSM215340 | Fibroblasts_SLx2119_rep2 | 8.7 | 24 |
GSM215341 | Fibroblasts_SLx2119_rep3 | 1.7 | 5 |